As part of a Compassionate Expanded access program, such advanced NET patients progressing under conventional therapy can benefit from this therapy program here at UPMC Presbyterian. This new imaging tool also allows our oncologists to determine if some of their advanced NET patients could benefit from a new Peptide Receptor Radionuclide Therapy (PRRT) that specifically targets somatostatin receptors in these cancer cells. After its introduction in our imaging centers at Hillman and Presby, there has been an overwhelming response from our patients and oncologists from within the UPMC system and also from outside the region. Prior to your scan: Nothing but water 4 hours prior to scan.

A plethora of scientific data have advocated for its use in clinical staging and management of such NETs. NETSPOT - GALLIUM 68 DOTATE PET/CT Prep Sheet. For clinical questions on the scan, email or call 84.

We want to get the word out that we are excited to have this test as it’s going to help the patients and the clinicians, Dr. Symptoms often resemble those of other diseases, like sweating, diarrhea, abdominal pain, and GI bleeding. Cormier has been reaching out to oncology groups to inform them about the new GA68 Dotatate PET/CT scan. They have become the second most common cancer of the gastrointestinal tract. There are several types of NETs, but most occur throughout the gastrointestinal tract and lungs.

This novel molecular imaging technology Ga-68 DOTATATE ( Netspot ™) had been widely anticipated by our oncologists and patients alike. vipivotide tetraxetan), NETSPOT (gallium Ga 68 dotatate), and LOCAMETZ (gallium Ga 68 gozetotide), as well as general AAA PatientCONNECT materials. Neuroendocrine Tumors (NETs) are a group of uncommon tumors. NETSPOT is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor. As part of our long standing commitment and dedication to cancer care, we are very excited to announce that UPMC ( Hillman cancer center and Presbyterian) is the first hospital system in Western Pennsylvania and one of the first 10 centers in the country to offer a new cutting-edge technology for imaging Neuroendocrine tumors (NETs).

Netspot ga68